To study the effectiveness of Tablet Fluuconazole in superficial fungal infection (Tinea Corporis)

A prospective clinical study to explore the oral Fluconazole resistance in Tinea Corporis

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

CTRI

Registry ID

CTRI/2020/05/025442

Enrollment

Registered

2020-05-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Single or multiple annular erythematous plaques 2.KOH mount positive for Tinea corporis 3.No previpous exposure to Fluconazole 4.Comorbidities like Diabetes mellitus, obesity and other endocrine disorders.

Exclusion criteria

Exclusion criteria: 1.Large cofluent lesions. 2.History of previous exposure to Fluconazole 3.Patients on medications like steroide, antihistamines, aspirin, immunomodulators,statins,NSAIDS. 4.Patients on chronic medications for TB, HIV, Leprosy

Design outcomes

Primary

Measure	Time frame
Clinical cure of Pruritus,Erythema and ScalingTimepoint: At 15th day of Fluconazole Treatment	—

Secondary

Measure	Time frame
To assess the resistance of Fluconazole in patients with comorbidities like Diabetes mellitus, obesity and other endocrine disordersTimepoint: At 15th day of Fluconazole treatment;To observe the side effects of Fluconazole following administration of FluconazoleTimepoint: During the 15 days of Fluconazole therapy;To study the role of plasma levels of Fluconazole if there is a resistance and no clinical cure with FluconazoleTimepoint: HPLC - analysis of Fluconazole levels, skin scrapings-culture	—

Measure

Time frame

To assess the resistance of Fluconazole in patients with comorbidities like Diabetes mellitus, obesity and other endocrine disordersTimepoint: At 15th day of Fluconazole treatment;To observe the side effects of Fluconazole following administration of FluconazoleTimepoint: During the 15 days of Fluconazole therapy;To study the role of plasma levels of Fluconazole if there is a resistance and no clinical cure with FluconazoleTimepoint: HPLC - analysis of Fluconazole levels, skin scrapings-culture

—

Countries

India

Contacts

Public ContactDr K BHUVANESWARI

PSG Institute of Medical Sciences and Research

nandabhuvana@gmail.com9894769934

Outcome results